This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Conry, R. M. Articles by LoBuglio, A. F. Search for Related Content PubMed PubMed Citation Articles by Conry, R. M. Articles by LoBuglio, A. F.

Human Autoantibodies to Carcinoembryonic Antigen (CEA) Induced by a Vaccinia-CEA Vaccine¹

Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, Alabama 35294-3300 [R. M. C., K. O. A., S. E. M., D. R. S., A. F. L.], and Department of Dermatology, Faculty of Medicine, Kyushu University, Fukuoka 812-82 Japan [S-w. L.]

Carcinoembryonic antigen (CEA) is a well-characterized oncofetal glycoprotein whose overexpression by human adenocarcinomas has been a target for cancer immunotherapy. Limited information is available regarding the ability of patients to mount an antibody response to this self-antigen following vaccination. Recombinant vaccinia viruses encoding full-length or internally deleted cDNAs for human CEA were used to vaccinate 32 patients with CEA-expressing adenocarcinomas, predominantly of colorectal origin. CEA-specific autoantibodies were induced by vaccination in 7 of 32 patients. None of the patients had CEA antibodies detected before vaccination. CEA specificity of the antibodies initially identified by ELISA was confirmed by competitive inhibition analysis as well as recognition of recombinant CEA produced in baculovirus-infected insect cell cultures and human cell cultures by Western blot. The CEA autoantibodies were predominantly IgG1, with a minority of patients also demonstrating IgM autoantibodies. CEA antibodies were of low titer and low avidity, based on competitive inhibition assays. These autoantibodies did not affect clinical serum CEA protein quantitation. Furthermore, elevated serum CEA levels commonly encountered in patients with advanced adenocarcinoma did not hinder detection of low avidity polyclonal CEA antibodies. CEA antibodies such as those induced in these pilot trials are projected to have modest antitumor activity. Thus, additional Phase I/II trials of recombinant vaccinia-CEA with alternative prime-boost approaches and/or augmentation strategies are warranted in an effort to enhance the frequency and avidity of CEA-specific autoantibodies and cytolytic T cells before Phase III trials.

This article has been cited by other articles:

				S. Mosolits, G. Ullenhag, and H. Mellstedt Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results Ann. Onc., June 1, 2005; 16(6): 847 - 862. [Abstract] [Full Text] [PDF]

				G. J. Ullenhag, J.-E. Frodin, M. Jeddi-Tehrani, K. Strigard, E. Eriksson, A. Samanci, A. Choudhury, B. Nilsson, E. D. Rossmann, S. Mosolits, et al. Durable Carcinoembryonic Antigen (CEA)-Specific Humoral and Cellular Immune Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant CEA and Granulocyte/Macrophage Colony-Stimulating Factor Clin. Cancer Res., May 15, 2004; 10(10): 3273 - 3281. [Abstract] [Full Text] [PDF]

				C. L Smith, N. Dulphy, M. Salio, and V. Cerundolo Immunotherapy of colorectal cancer Br. Med. Bull., December 1, 2002; 64(1): 181 - 200. [Abstract] [Full Text] [PDF]

				D. H Palmer, M.-J. Chen, and D. J Kerr Gene therapy for colorectal cancer Br. Med. Bull., December 1, 2002; 64(1): 201 - 225. [Abstract] [Full Text] [PDF]

				R. M. Conry, D. T. Curiel, T. V. Strong, S. E. Moore, K. O. Allen, D. L. Barlow, D. R. Shaw, and A. F. LoBuglio Safety and Immunogenicity of a DNA Vaccine Encoding Carcinoembryonic Antigen and Hepatitis B Surface Antigen in Colorectal Carcinoma Patients Clin. Cancer Res., September 1, 2002; 8(9): 2782 - 2787. [Abstract] [Full Text] [PDF]

				N. L. Berinstein Carcinoembryonic Antigen as a Target for Therapeutic Anticancer Vaccines: A Review J. Clin. Oncol., April 15, 2002; 20(8): 2197 - 2207. [Abstract] [Full Text] [PDF]

				G. J. Ullenhag, J.-E. Frodin, K. Strigard, H. Mellstedt, and C. G. M. Magnusson Induction of IgG Subclass Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant Carcinoembryonic Antigen Cancer Res., March 1, 2002; 62(5): 1364 - 1369. [Abstract] [Full Text] [PDF]

				Y. Hu, J. Lee, J. A. McCart, H. Xu, B. Moss, H. R. Alexander, and D. L. Bartlett Yaba-Like Disease Virus: an Alternative Replicating Poxvirus Vector for Cancer Gene Therapy J. Virol., November 1, 2001; 75(21): 10300 - 10308. [Abstract] [Full Text] [PDF]

				M. Gorschluter, C. Ziske, A. Glasmacher, and I. G. H. Schmidt-Wolf Current Clinical and Laboratory Strategies to Augment the Efficacy of Immunotherapy in Multiple Myeloma Clin. Cancer Res., August 1, 2001; 7(8): 2195 - 2204. [Abstract] [Full Text] [PDF]

				Y. L. Yip, G. Smith, J. Koch, S. Dubel, and R. L. Ward Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design J. Immunol., April 15, 2001; 166(8): 5271 - 5278. [Abstract] [Full Text] [PDF]